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Abstract
Background: Vascular calcification is an indicator of elevated cardiovascular risk. Vascular smooth muscle cells (VSMCs), the
predominant cell type involved in medial vascular calcification, can undergo phenotypic transition to both osteoblastic and
chondrocytic cells within a calcifying environment.
Methodology/Principal Findings: In the present study, using in vitro VSMC calcification studies in conjunction with ex vivo
analyses of a mouse model of medial calcification, we show that vascular calcification is also associated with the expression
of osteocyte phenotype markers. As controls, the terminal differentiation of murine calvarial osteoblasts into osteocytes was
induced in vitro in the presence of calcifying medium (containing ß-glycerophosphate and ascorbic acid), as determined by
increased expression of the osteocyte markers DMP-1, E11 and sclerostin. Culture of murine aortic VSMCs under identical
conditions confirmed that the calcification of these cells can also be induced in similar calcifying medium. Calcified VSMCs
had increased alkaline phosphatase activity and PiT-1 expression, which are recognized markers of vascular calcification.
Expression of DMP-1, E11 and sclerostin was up-regulated during VSMC calcification in vitro. Increased protein expression of
E11, an early osteocyte marker, and sclerostin, expressed by more mature osteocytes was also observed in the calcified
media of Enpp12/2 mouse aortic tissue.
Conclusions/Significance: This study has demonstrated the up-regulation of key osteocytic molecules during the vascular
calcification process. A fuller understanding of the functional role of osteocyte formation and specifically sclerostin and E11
expression in the vascular calcification process may identify novel potential therapeutic strategies for clinical intervention.
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Introduction
Vascular calcification is a marker of increased cardiovascular
risk in a number of diseases, including diabetes, atherosclerosis and
end-stage renal disease [1–3]. The process of vascular calcification
shares many similarities with that of bone formation [1,2].
Chondrocytes and osteoblasts calcify their extracellular matrix
(ECM) during endochondral bone formation by promoting the
formation of crystalline hydroxyapatite, through a series of
physico-chemical and biochemical processes.
Osteocytes are terminally differentiated osteoblasts and make up
90% of the cells present within bone. They are distinctive and
isolated cells that are embedded within the bone matrix. Although
the precise actions of osteocytes in bone have yet to be fully
elucidated, these cells play pivotal mechanomodulatory roles in
directing bone formation and bone resorption in response to load-
bearing [4]. Osteocytes also have a reported role in mi-
neral homeostasis. They are capable of modifying the matrix
environment around them [5] and produce calcification modifying
hormones and growth factors [6,7]. There is also a requirement
for the local production of matrix metalloproteinases and
modulators of calcification in the osteocyte’s canalicular–lacuna
environment for healthy osteocyte function [8].
Within the past two decades, a number of osteocyte markers
have been identified, including dentin matrix protein-1 (DMP-1),
E11 and sclerostin [6,7]. DMP-1 is an ECM protein member of
the SIBLING family and recent work has emphasized the relative
osteocyte specificity of DMP-1 and implicated it in osteocyte
function and signalling [9]. DMP-1 is known to be produced in
response to mechanical loading [10] and DMP-1 ablation induces
a hypomineralized phenotype associated with elevated levels of
circulating FGF-23 and defective osteocyte network formation
[11]. DMP-1 produced by the osteocyte regulates FGF-23
production, and acts through a bone-kidney axis to control
phosphate homeostasis [11].
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E11, also called podoplanin, OTS-8, gp38, or PA2.25 based on
its identification in different tissues, is a mucin-type glycoprotein
with O-glycosylation and high sialic acid content [12]. E11 is
highly expressed in osteocytes that are in the process of embedding
within the ECM or have recently embedded [13]. It is also
expressed in several other cell types with a dendritic morphology,
including kidney podocytes, type II lung alveolar cells, and cells of
the choroid plexus [7]. Indeed, a functional link between E11
expression and osteocyte dendrite formation was evident in
osteoblasts in which E11 expression had been reduced. This gene
silencing approach resulted in the inhibitition of cytoplasmic
processes development [13]. E11 has also been proposed to
function in the adhesion of cells to the bone matrix [14].
More mature deeply embedded osteocytes express high levels of
sclerostin, the glycoprotein product of the SOST gene [15]. Loss-
of-function mutations in SOST cause progressive bone overgrowth
in humans [16]. SOST-null mice also have a high bone mass
phenotype [17]. These negative effects of sclerostin on osteoblas-
togenesis and bone formation are most likely exerted through its
antagonizing effects on LRP5 actions, a key activator of the Wnt/
b-catenin signalling pathway [15,18].
A number of studies have reported that vascular smooth muscle
cells (VSMCs), the predominant cell type involved in vascular
calcification, can undergo phenotypic transition to osteoblastic and
chondrocytic cells in a calcified environment [19–23]. Cells of an
osteocyte phenotype have been observed in Mo¨nckeberg’s sclerosis
lesions, which are characterized by medial calcification of
peripheral arteries [24]. However, it has yet to be established
whether VSMC calcification involves a transition to an osteocyte
phenotype. Therefore, in the present study we have undertaken in
vitro VSMC calcification studies, in conjunction with ex vivo
analyses of a mouse model of medial calcification and demon-
strated that vascular calcification is associated with the appearance
of an osteocyte phenotype.
Materials and Methods
Ethics statement
All animal experiments were approved by The Roslin Institute’s
Animal Users Committee and the animals were maintained in
accordance with Home Office guidelines for the care and use of
laboratory animals.
Primary murine calvarial osteoblast isolation
Primary mouse osteoblasts were obtained by sequential enzyme
digestion of excised calvarial bones from 3-d-old wild-type C57BL/
6 mice using a four-step process [1 mg/ml collagenase type II in
Hanks’ balanced salt solution (HBSS) for 10 min; 1 mg/ml
collagenase type II in HBSS for 30 min; 4 mM ethylenediamine-
tetraacetic acid (EDTA) for 10 min; 1 mg/ml collagenase type II in
HBSS for 30 min]. The first digest was discarded and the cells
subsequently obtained were resuspended in growth medium
consisting of a-MEM (Invitrogen, Paisley, UK) supplemented with
10% FCS (Invitrogen) and 1% gentamycin (Invitrogen). Cells were
cultured for 4 d in a humidified atmosphere of 95% air/5% CO2 at
37uC in T75 tissue culture flasks (Greiner Bio-One, GmbH,
Frickenhausen, Baden-Wu¨rttemberg, Germany) until confluent.
Primary murine VSMC isolation
Primary VSMCs were isolated from aortae dissected from wild-
type C57BL/6 mice at 5 wks of age. The adventitia was removed
and the aorta cut open to expose the endothelial layer [22]. Tissues
from eight animals were pooled for digestion with 1 mg/ml trypsin
for 10 min to remove any remaining adventitia and endothelium.
This was followed by incubation overnight at 37uC in a humidified
atmosphere of 95% air/5% CO2 in growth medium. Tissues were
then digested in 425 U/ml collagenase type II for 5 h. Before
experimentation, isolated VSMCs were expanded in growth
medium for two passages in T25 tissue culture flasks (Greiner Bio-
One) coated with 0.25 mg/cm2 murine laminin (Sigma, Poole, UK)
to promote maintenance of the contractile differentiation state [25].
Primary murine osteoblast and VSMC culture
Osteoblasts and VSMCs were seeded at a density of 1.56104
cells/cm2. At confluency (day 0), growth medium was supple-
mented with 2.5 mM ß-glycerophosphate (ßGP) and 50 mg/ml
ascorbic acid for up to 28 d to induce matrix calcification.
Incubation was at 37uC in a humidified atmosphere of 95% air/
5% CO2 and the medium was changed every second/third day.
Detection of calcification
Calcium deposition was evaluated by staining the cell-matrix
monolayer with alizarin red [26,27]. Cells were washed twice with
phosphate buffered saline (PBS), fixed in 4% paraformaldehyde
for 5 min at 4uC, stained with 2% alizarin red (pH 4.2) for 5 min
at room temperature and rinsed with distilled water. Alizarin red
stained cultures were extracted with 10% cetylpyridium chloride
for 10 min and the O.D. was determined at 570 nm by
spectrophotometery (Multiskan Ascent, Thermo Electron Corpo-
ration, Vantaa, Finland).
The matrix was also decalcified in 0.6 N HCL for 24 h, and free
calcium determined colorimetrically using a commercially available
kit (Randox Laboratories Ltd, Crumlin, County Antrim, UK) and
corrected for total protein concentration. The protein content of the
cultures was measured using the Bio-Rad protein assay reagent (Bio-
Rad Laboratories, Hertfordshire, UK) based on the Bradford dye
binding procedure, and gamma globulin was used as standard [28].
Alkaline Phosphatase (ALP) activity
Cell layers were lysed with 0?9% NaCl and 0?2% Triton X-100
and centrifuged at 12 000 g for 15 min at 4uC. The supernatant
was assayed for protein content and ALP activity. Enzyme activity
was determined by measuring the cleavage of 10 mM p-nitrophenyl
phosphate (pNPP) at 410 nm using a commercially available kit
(Thermo Trace, Melbourne, Australia). Total ALP activity was
expressed as nmoles pNPP hydrolysed/min/mg protein [29].
Analysis of gene expression using quantitative RT-PCR
RNA was extracted from cells using RNeasy total RNA (Qiagen
Ltd, Crawley, West Sussex, UK), according to the manufacturer’s
instructions. For each sample, total RNA content was assessed by
absorbance at 260 nm and purity by A260/A280 ratios. RNA was
reverse transcribed and the PCR reaction undertaken as described
previously [30,31]. All genes were analyzed with the SYBR green
detection method using the Stratagene Mx3000P real-time QPCR
system (Stratagene, CA, USA). Each PCR was run in triplicate. All
gene expression data were normalized against Gapdh and the
control values expressed as 1 to indicate a precise fold change
value for each gene of interest. Primers for PiT-1 (Forward 59CAC
TCA TGT CCA TCT CAG ACT39, Reverse 59CGT GCC AAA
GAA GGT GAA C39), ALP (Akp2) (Forward 59GGG ACG AAT
CTC AGG GTA CA39, Reverse 59AGT AAC TGG GGT CTC
TCT CTT T39), E11 (Forward 59AAC AAG TCA CCC CAA
TAG AGA TAA T39 Reverse 59CTA ACA AGA CGC CAA
CTA TGA TTC39), SOST, Dmp-1 (Qiagen; sequence not
disclosed) and Gapdh (Primer Design, Southampton, UK; sequence
not disclosed) were used.
Osteocyte Markers in Aortic Calcification
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Figure 1. In vitro calcification of murine calvarial osteoblast cells cultured for 28 d under calcifying conditions. Quantification of (a)
alizarin red staining (calcium deposition) and (b) Alkaline phosphatase activity (mean moles pNPP hydrol/min/mg protein). (c) Fold changes in PiT-1
mRNA expression in cultured osteoblasts. Results are presented as mean+/2S.E.M. *** P,0.001 compared with day 0.
doi:10.1371/journal.pone.0019595.g001
Osteocyte Markers in Aortic Calcification
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Western blotting
Cultured cells were lysed in RIPA buffer (Invitrogen) containing
‘‘complete’’ protease inhibitor cocktail according to manufacture’s
instructions (Roche, East Sussex, UK). Immunoblotting was
undertaken as previously described [27,31]. Nitrocellulose mem-
branes were probed overnight at 4uC with anti-sclerostin or anti-
E11 primary antibody (1:1000 dilution in 5% BSA), (R&D
Systems, Abingdon, UK), washed in TBST and incubated with
anti-goat IgG-peroxidase (DAKO, Glostrup, Denmark) for 1 h
(1:1000 dilution in 5% milk). The immune complexes were
visualised by enhanced chemiluminescence (ECL) (GE Health-
care, Buckinghamshire, UK). Membranes were then washed in
‘stripping buffer’ (Pierce, Rockford, Il, USA) and re-probed for 1 h
for ß-actin expression (1:5000 dilution in 5% milk; anti ß-actin
clone AC15; Sigma). After washing, membranes were incubated
with anti-mouse IgG-peroxidase for 1 h (Sigma).
Maintenance of Enpp12/2 mice
The generation and characterization of the ectonucleotide
pyrophosphatase/phosphodiesterase 1 null (Enpp12/2) mouse has
been previously described [32]. To determine genotypes, genomic
DNA was isolated from ear clips and analyzed using PCR
protocols developed by Genetyper (Genetyper, New York, USA).
Immunohistochemistry
Tibiae and aortae were dissected from 22 week-old Enpp12/2
and Enpp1+/+ wild-type mice that had been euthanized. After
fixation in 70% ethanol the tibiae were decalcified in 10% EDTA
(pH 8.0) for 4 wks at 4uC. Tissues were finally dehydrated and
embedded in paraffin wax before sectioning at 5 mm (tibiae) or
4 mm (aortae) using standard procedures. For histological analysis,
sections were de-waxed in xylene and antigen retrieval was
achieved by treatment with 0.1% trypsin for 10 min. Endogenous
peroxidises and non-specific antibody binding were blocked before
overnight incubation at 4uC with 0.5 mg IgG/ml anti-sclerostin or
anti-E11 antibodies (R&D Systems). The slides were then washed
in PBS, and incubated with rabbit anti-goat IgG peroxidise (1:200
dilution) using the Vectastain ABC kit (Vector Laboratories,
Peterborough, UK) following the manufacturer’s instructions. The
sections were finally dehydrated, counterstained with haematox-
ylin and eosin and mounted in DePeX. Control sections were
incubated with non-immune goat IgG (0.5 mg IgG/ml) in place of
the primary antibody.
Statistical analysis
General Linear Model analysis and the Students t-test were used
to assess the data. All data are expressed as the mean+/2S.E.M.
Statistical analysis was performed using Minitab 15. P,0.05 was
considered to be significant.
Results
Differentiation of osteoblasts into osteocytes in vitro
Calvarial osteoblasts at confluency had negligible amounts of
alizarin red staining (calcium deposition) (Fig. 1a) and ALP activity
(Fig. 1b). Further culture in calcifying conditions for an additional
7, 14, 21 and 28 d resulted in significant increases in both ALP
activity and alizarin red staining. In addition, mRNA expression of
Figure 2. Up-regulation of osteocyte markers during in vitro calcification of murine calvarial osteoblast cells cultured for 28 d under
calcifying conditions. Fold changes in mRNA expression of (a) Dmp-1, (b) SOST and (c) E11. (d) Sclerostin and E11 protein expression in
corresponding cultured osteoblasts. Results are presented as mean+/2S.E.M. * P,0.05; *** P,0.001 compared with day 0.
doi:10.1371/journal.pone.0019595.g002
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Figure 3. In vitro calcification of murine aortic VSMCs cultured for 28 d under calcifying conditions. Quantification of (a) alizarin red
staining (calcium deposition) and (b) Alkaline phosphatase activity (mean moles pNPP hydrol/min/mg protein). (c) Fold changes in PiT-1 mRNA
expression in cultured VSMCs. Results are presented as mean+/2S.E.M. ** P,0.01; ***P,0.001 compared with day 0.
doi:10.1371/journal.pone.0019595.g003
Osteocyte Markers in Aortic Calcification
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the type III sodium-dependent phosphate transporter PiT-1, a
gene associated with osteoblast mineralization, was significantly
increased at the end of the culture period (Fig. 1c). These data
confirm the formation of calcified matrix in calvarial osteoblasts
over the 28-day culture period.
mRNA expression of Dmp-1 and E11 was observed at all time
points during the culture period. By 7 d, a significant increase in
both Dmp-1 (29.5 fold; P,0.001); Fig. 2a) and E11 (2.2 fold;
P,0.001); Fig. 2b) mRNA expression was noted. This increased
expression was maintained throughout the culture period. SOST
expression was also observed at all time points, with a significant
increase in expression also seen by 7 d (3.4 fold; P,0.001; Fig. 2c).
Comparable changes in sclerostin protein expression were
observed, however E11 protein expression appeared to reduce
following 21d in culture (Fig. 2d), which may be associated with
post-transcriptional or post-translational regulation of expression.
Previous studies have reported that E11 protein is degraded by the
calpain family of proteinases [33]. These expression studies
demonstrate the terminal differentiation of calvarial osteoblasts
into the osteocyte phenotype in vitro.
VSMC calcification in vitro is associated with an osteocyte
phenotype
Alizarin red staining (calcium deposition) (Fig. 3a) and ALP activity
(Fig. 3b) in murine aortic VSMCs were negligible at 0 d of culture.
Significant increases in both matrix mineralization and ALP activity
were noted following 7, 14, 21 and 28 d of culture in calcifying
medium. A significant increase in mRNA expression of PiT-1 was
seen by 7 d (3.0 fold; P,0.001; Fig. 3c). These results confirm the in
vitro calcification of aortic VSMCs over the 28-day culture period.
Dmp-1 and E11 mRNA expression was noted at all time points.
By 7 d, a significant increase in both Dmp-1 (61.8 fold; P,0.001);
Fig. 4a) and E11 (2.2 fold; P,0.001); Fig. 4b) mRNA expression
was observed, which was maintained throughout the 28 d culture
period. SOST expression was also observed at all time points, with
a significant increase in expression also seen by 7 d (234.8 fold;
P,0.001; Fig. 4c). The temporal E11 protein expression mirrored
that of E11 gene expression with higher levels noted from day 7
onwards (Fig. 4d). Significant sclerostin protein expression was
however only noted at day 28 of culture. (Fig. 4d). These studies
show that calcification caused by elevated phosphate levels
(through the addition of bGP) induces VSMCs to undergo an
osteocytic phenotype transition in vitro.
Further examination of aortic VSMC osteocyte marker
expression during matrix calcification was achieved in a
comparison of VSMCs maintained under calcifying and non-
calcifying conditions. The calcium content (P,0.05; Fig. 5a) and
PiT-1 gene expression (P,0.001; Fig. 5b) of VSMCs cultured for
21 d in the presence of ßGP was significantly increased in
comparison to non-calcifying control cells. Also, significant
increases in mRNA (P,0.001; Fig.5b) and protein (Fig. 5c),
expression of E11 and sclerostin expression were observed in the
calcifying cultures. These studies further confirm that phosphate
induced in vitro calcification of aortic VSMCS is associated with the
expression of markers of the osteocyte phenotype.
Figure 4. Up-regulation of osteocyte markers during in vitro calcification of murine aortic VSMCs cultured for 28 d under calcifying
conditions. Fold changes in mRNA expression of (a) Dmp-1, (b) SOST and (c) E11. (d) Sclerostin and E11 protein expression in corresponding cultured
osteoblasts. Results are presented as mean+/2S.E.M. * P,0.05; ** P,0.01; *** P,0.001 compared with day 0.
doi:10.1371/journal.pone.0019595.g004
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Osteocyte markers are present in the calcified aorta from
the Enpp12/2 mouse
The association of an osteocyte phenotype with vascular
calcification was further strengthened by examination of the
Enpp12/2 mouse. This mouse model shows decreased levels of
the mineralization inhibitor pyrophosphate, with phenotypic
features including significant alterations in bone mineralization
in long bones and calvariae, and pathologic, severe perispi-
nal soft tissue and medial arterial calcification [32]. Calcification
in the medial layer of the Enpp12/2 aorta was confirmed
by alizarin red staining (Fig. 6a), with no staining observed in
wild-type controls (Fig. 6b). Following confirmation of sclerostin
(Fig. 7a) and E11 (Fig. 7b) protein expression in osteocytes and
associated canaliculi within cortical bone, expression of both
proteins was also detected in the Enpp12/2 calcified aortic
media (Fig. 6c&d and Fig. 6g&h respectively). No positive
staining for E11 or sclerostin was seen in wild-type mice
(Fig. 6e&f and Fig. 6i&j respectively) or control sections
incubated with IgG only (Fig. 6l). These immunolocalisation
studies verify our in vitro data, and confirm the up-regulation of
markers associated with an osteocyte phenotype during the
vascular calcification process.
Figure 5. In vitro calcification of murine aortic VSMCs cultured for 21 d in the presence or absence of ßGP. (a) Calcium content (mM/mg
protein). (b) Fold changes in mRNA expression of PiT-1, SOST, E11 and Dmp-1. (c) Sclerostin and E11 protein expression in corresponding cultured
VSMCs. Results are presented as mean+/2S.E.M. * P,0.05; *** P,0.001 compared with absence of ßGP.
doi:10.1371/journal.pone.0019595.g005
Osteocyte Markers in Aortic Calcification
PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e19595
Discussion
Despite the clinical importance of vascular calcification, the
precise biochemical processes regulating this pathological process
are not yet fully understood. A number of studies have shown that
VSMCs, the predominant cell type involved in vascular calcifica-
tion, can undergo phenotypic transition to osteoblastic and
chondrocytic cells in a calcified environment [19–23]. However,
it has yet to be established whether VSMC calcification is
associated with the terminal differentiation of the nascent
Figure 6. Emergence of osteocytic markers in the calcified aorta from the Enpp12/2 mouse in vivo. Medial aortic calcification was
detected by alizarin red staining (arrows) in (a) Enpp12/2 tissue compared to (b) Enpp1+/+ control. Increased protein expression of (c, d) E11 and (g, h)
Sclerostin was observed in the calcified media of Enpp12/2 aortic tissue (arrows). No expression of (e, f) E11 and (i, j) Sclerostin was detected in the
non-calcified media of the Enpp1+/+ control. Representative images of (K) Enpp12/2 tissue and (l) Enpp1+/+ negative control tissues. Scale
bars = 50 mm.
doi:10.1371/journal.pone.0019595.g006
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osteoblasts to an osteocyte phenotype. Such terminal differentia-
tion would strongly imply that similar osteoblast phenotypic
transitions observed in bone also occur in vascular tissue, which
would be suggestive of common regulatory and differentiation
pathways in both tissues.
In the present study, quantitative alizarin red staining of
calcium deposition confirmed the formation of calcified matrix in
murine calvarial osteoblast cultures, induced by treatment with
ascorbic acid and ßGP. This is in agreement with previous reports
[34,35]. In addition, calvarial cells cultured under calcifying
conditions showed increased ALP activity and expression of PiT-1
which are recognised regulators of osteoblast matrix calcification
[34–36].
Culture of murine VSMCs under identical conditions con-
firmed that the calcification of the matrix of these cells can also be
induced by ßGP and ascorbic acid. Calcified VSMC also showed
increased ALP activity and PiT-1 expression, which are recog-
nized regulators of vascular calcification. Interestingly, the
temporal expression pattern of PiT-1 differed notably between
the osteoblasts and VSMCs. This may be a result of PiT-1 being
the predominant sodium-dependent phosphate co-transporter
expressed in VSMCs [37]. Increased PiT-1 expression leads to
elevated intracellular phosphate and induces the osteogenic
conversion of VSMCs [37]. Conversely, down-regulation of PiT-
1 expression by gene silencing has been shown to reduce
phosphate uptake by VSMCs and inhibit phosphate-induced
VSMC phenotypic transition and matrix calcification [37]. ALP
has an important role in vascular calcification through its ability to
generate phosphate, and by decreasing levels of the calcification
inhibitor pyrophosphate in blood vessels and has been proposed as
a therapeutic target for medial vascular calcification [34,38].
In order to establish whether VSMC calcification involves a
transition to an osteocyte phenotype, the expression patterns of
DMP-1, E11 and sclerostin were investigated. Increased expres-
sion levels of Dmp-1, E11 and SOST mRNA were noted after 7
days of culture in both osteoblasts and VSMCs. This increased
expression was maintained throughout the culture period.
However, temporal differences in sclerostin and E11 protein
expression were observed between osteoblasts and VSMCs and
this reflects the likelihood of osteoblasts more readily undergo this
transistion compared to VSMCs. Interestingly E11 protein
expression in osteoblasts appeared to reduce following 21 days
in culture, which may be associated with post-transcriptional or
post-translational regulation of expression.
These studies show that calcification caused by elevated
phosphate levels induces VSMCs to undergo an osteocytic
phenotype change. This is in agreement with studies in bone,
which have shown that calcification drives osteocyte formation
[39]. However, it has also been proposed that calcification may be
directed by cells that are already differentiating into osteocyte-like
cells [40]. Further imaging studies examining the calcification
dynamics in VSMCs would establish whether calcification is
directed by VSMCs undergoing an osteocytic phenotype change.
To our knowledge, this is the first report indicating that the
osteocyte markers DMP-1, E11 and sclerostin are up-regulated
during VSMC calcification in vitro. These in vitro data were
confirmed and extended by studying an in vivo mouse model of
vascular calcification. Mice lacking ecto-nucleotide pyrophospha-
tase/phosphodiesterases-1 (NPP1, a.k.a PC-1), a major generator
of extracellular pyrophosphate, spontaneously develop articular
cartilage, perispinal, and medial aortic calcification at a young age
[41]. These NPP1 knockout mice (Enpp12/2) share phenotypic
features with a human disease, idiopathic infantile arterial
calcification [42,43]. In the present study, our immunohistochem-
ical approach demonstrated increased expression of both sclerostin
and E11 in the calcified media of Enpp12/2 aortic tissue. This data
is supported by the expression of sclerostin in CMV-Msx2
transgenic mice, which show extensive cardiovascular calcification
[44]. Additionally, a comprehensive analysis of extracellular space
components comprising the vascular proteome in humans recently
identified the presence of sclerostin in aortic extracts [45].
Sclerostin has also been shown to bind to and influence the
activity of the ECM protein, cysteine-rich protein 61 (Cyr61) [46].
Sclerostin potentiates Cyr61-mediated cell growth and vascular
migration and alters Cyr61-mediated cellular adhesion [46].
Sclerostin may therefore play a key functional role in both
physiological and pathological vascular tissue biology.
This study has demonstrated the up-regulation of molecules
associated with the osteocyte phenotype in the Enpp12/2 mouse
model of aortic medial calcification. Further studies are required
to verify the phenotype transition of VSMCs to osteocytes in the
vascular calcification process using additional pathological animal
models, such as atherosclerosis and chronic kidney disease.
A fuller understanding of the importance of osteoblast terminal
differentiation in this pathological process, and in particular
functional studies to determine the role of sclerostin and E11, will
lead to a better understanding of the etiology of VSMC
calcification. Also, the identification of E11 as a potential driver
Figure 7. Confirmation of osteocytic markers in the mouse tibia in vivo. Protein expression of (a) Sclerostin and (b) E11 was confirmed in
osteocytes of a positive control mouse tibia (arrows). (c) Representative image of appropriate negative control. Scale bars = 100 mm.
doi:10.1371/journal.pone.0019595.g007
Osteocyte Markers in Aortic Calcification
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of osteocytogenesis in vascular calcification may stimulate the
development of novel potential therapeutic strategies for the
inhibition of vascular calcification.
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